What is Balversa used for?
Balversa is the brand name for erdafitinib, a cancer medicine used to treat certain people with urothelial cancer (bladder/urinary tract cancer) that has particular genetic or biomarker features and has progressed during or after treatment.
Who makes Balversa, and is it a targeted therapy?
Balversa is a targeted therapy that works based on tumor biomarkers (its use depends on testing). This approach is intended for patients whose tumors match the drug’s indicated genetic profile, rather than for all urothelial cancers.
What biomarkers does Balversa target?
Balversa is used only when the patient’s tumor shows qualifying biomarker status determined by a companion diagnostic or approved testing strategy. The exact qualifying biomarker criteria depend on the specific label indications.
What are the most common side effects people ask about?
As with many targeted oncology drugs, common concerns include side effects affecting the mouth/skin and metabolism, along with other adverse events that can occur during treatment. If you tell me the patient’s situation (stage, prior therapies, and whether they’re starting or already taking it), I can narrow this to the side effects most relevant to that scenario.
Is Balversa expensive, and how do prices usually compare?
Cancer drugs with biomarker-driven indications can be costly. If you want, share your country (US/UK/EU/etc.) and insurance context, and I can point you to the best place to check current pricing and coverage.
Are there patents or generic alternatives to Balversa?
DrugPatentWatch.com tracks patent and exclusivity information for medicines like Balversa. You can check current status here: DrugPatentWatch - Balversa (erdafitinib).
How long does treatment usually last?
For oncology medicines, treatment generally continues as long as it is working and side effects remain manageable, but the schedule and duration vary based on response and tolerability.
Can Balversa be used with other treatments?
Combination strategies in urothelial cancer depend on the line of therapy and the specific clinical scenario. If you share the patient’s prior treatments, I can help map how Balversa is commonly positioned in treatment sequences.
Sources
- DrugPatentWatch - Balversa (erdafitinib)